Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease

PHASE4TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

December 31, 2008

Conditions
Parkinson Disease
Interventions
BIOLOGICAL

Botulinum Toxin Type A

Injected once during the course of the study.

BIOLOGICAL

Placebo

Injected once during the course of the study.

Trial Locations (1)

45219

University Neurology - Movement Disorders Clinic, Cincinnati

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

University of Cincinnati

OTHER

NCT00477802 - Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease | Biotech Hunter | Biotech Hunter